2014年1月7日 康圣环球与以色列BioView签署协议，获得后者FISH检测产品在中国大陆和港澳台地区的独家权益，该检测通过分析痰标本筛选肺癌高危患者。去年Illumina也与康圣环球签署协议推广TruSight技术。

 

BioView and Kindstar Signs Agreement

BioView and Kindstar Signs Agreement

Rehovot, Israel – December 30, 2013 – BioView Ltd, (TASE: BIOV) and Kindstar Global (Kindstar) today announced that the Companies have signed an agreement under which Kindstar will have an exclusive license to validate and implement BioView's Lung Cancer FISH test for an aid in early detection of Lung Cancer in its clinical laboratories.

Under the terms of the agreement Kindstar will purchase equipment and kits from BioView and will have an exclusive license to perform the test in China, Macau, Hong Kong and Taiwan. This agreement follows a successful Pilot Study done by Kindstar using the BioView assay. The agreement is for 3 years and can be automatically renewed if certain criteria are met.

The BioView Lung Cancer test analyzes sputum samples from subjects with a high risk for Lung Cancer using BioView's proprietary Target FISH technology. The test has shown a high concordance of results in several clinical studies.

The Dr. Alan Schwebel CEO of BioView: "This is a significant and important milestone for BioView. China and the other Countries covered in this agreement, which are among those having the highest incidence of Lung Cancer in the world, will be the first to have the BioView test available to aid in the early detection of Lung Cancer. We are honored to have the opportunity to partner with Global Kindstar which is one of the leading laboratories for esoteric testing in China. This agreement will be used as a model to offer the BioView Lung Cancer test in other Countries worldwide."

Dr. Shiang Huang, Founder and CEO of Kindstar said: "Kindstar is excited to offer services in China based on the BioView Target-FISH technology as an aid for the early detection of Lung Cancer. This test has promise to become a valuable diagnostic and prognostic tool for determining the risk of lung cancer for many patients, but particularly for smokers and will help broaden Kindstar's oncology test menu offering. We are excited to partner with BioView, a known leader in scanning and imaging of FISH assays."    

Lung Cancer Incidence in China

According to the 2012 Annual Report of Cancer Registration of China, Lung Cancer is ranked first in cancer morbidity and cancer mortality. There are approximately 700,000 new cases of Lung Cancer per year and less than 20% of them are diagnosed in the early stage. It is estimated that there are more than 575,000 deaths per year which are related to Lung disease in China.

About BioView Ltd.

Established in 2000, and led by an expert team of biologists, software engineers and physicists, BioView develops, manufactures and supplies cell imaging equipment, biological kits and software to medical institutes and universities.  BioView is a publicly traded company on the Israeli Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions. For more information about the BioView technology, and press related issues, please contact: alan@bioview.co.il

About Kindstar Global

Kindstar Global, with laboratory facilities in Beijing, Shanghai and Wuhan, provides esoteric diagnostic testing services to hospitals and physicians in every province of China. Kindstar is the first and largest esoteric diagnostic testing business in China, providing laboratory testing services to over 3,300 Chinese hospitals, including 930 tertiary hospitals (classification for largest leading hospitals). Kindstar is becoming the partner of choice to physicians in China for advanced diagnostics in many medical specialties including hematology, oncology, infectious diseases and medical genetics.